ReviewInternational journal of molecular sciences2019
Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Quail Egg-Based Supplements in Allergic Rhinitis: A Systematic Review of Clinical Studies.Nutrients · 2025Pooled it
- Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.International journal of clinical oncology · 2026Trial
- Effect of the Multi-Strain Probiotic SYN-53 in the Management of Allergic Rhinoconjunctivitis.Allergy · 2025Trial
- Trial
- Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers: A Wheal and Flare Study.International archives of allergy and immunology · 2022Trial
- Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.European journal of pediatrics · 2020Trial
- [Clinical observation of nasal spray allergen blocker combined with antihistamines in treatment of allergic rhinitis children].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2020Trial
- GPCR-Driven Muscarinic M1 and Histamine H1 Receptor Signaling Converging on the PI3K/Akt/mTOR Pathway: Functional Integration in Neuroinflammation and Myelin Repair in Multiple Sclerosis.Molecular neurobiology · 2026Review
- Montelukast and Bilastine Combination Therapy in Allergic Rhinitis: A Narrative Review of Evidence.Cureus · 2026Review
- Identification of Mitochondrial-Related Signature in Allergic Rhinitis: Novel Insights from Bioinformatics and Machine Learning.Journal of inflammation research · 2026Article
- Evaluation of the Antihistamine and Anti-Inflammatory Effects of a Nutraceutical Blend Based on Quercetin,Current issues in molecular biology · 2025Article
- Expert Panel Consensus Recommendations for Allergic Rhinitis in Patients with Asthma in India.Pulmonary therapy · 2025Article
- A comment on oral phenylephrine use in sinonasal pathologies.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Unravelling allergic rhinitis: exploring pathophysiology, advances in treatment, and future directions.Frontiers in allergy · 2025Review
- Prioritising patient-centred care in the management of chronic urticaria in Asia-Pacific countries.The World Allergy Organization journal · 2024Article
- Promoting patient-centred care in the management of allergic rhinitis in Asia-Pacific countries.The World Allergy Organization journal · 2024Article
- Twenty-five years: The fexofenadine clinical experience.The World Allergy Organization journal · 2024Review
- Review
- Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan.Hospital pharmacy · 2024Article
- Single-Domain Antibodies-Novel Tools to Study and Treat Allergies.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihistamines targeting the histamine H₁ receptor play an important role in improving and maintaining the quality of life of patients with allergic rhinitis. For more effective and safer use of second-generation drugs, which are recommended by various guidelines, a classification based on their detailed characteristics is necessary. Antihistamines for first-line therapy should not have central depressant/sedative activities. Sedative properties (drowsiness and impaired performance) are associated with the inhibition of central histamine neurons. Brain H₁ receptor occupancy (H₁RO) is a useful index shown to be correlated with indices based on clinical findings. Antihistamines are classified into non-sedating (<20%), less-sedating (20⁻50%), and sedating (≥50%) groups based on H₁RO. Among the non-sedating group, fexofenadine and bilastine are classified into "non-brain-penetrating antihistamines" based on the H₁RO. These two drugs have many common chemical properties. However, bilastine has more potent binding affinity to the H₁ receptor, and its action tends to last longer. In well-controlled studies using objective indices, bilastine does not affect psychomotor or driving performance even at twice the usual dose (20 mg). Upon selecting antihistamines for allergic rhinitis, various situations should be taken into our consideration. This review summarizes that the non-brain-penetrating antihistamines should be chosen for the first-line therapy of mild allergic rhinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.